Educational content only. This post explains how financial concepts and published data apply generally to healthcare practices — it does not constitute advice for your specific situation. Consult your accountant, lender, and relevant advisors before making any significant business or financial decisions.
For a dentist considering practice ownership, two main paths exist: acquiring an existing practice or starting one from scratch. The decision is often framed around preference or opportunity, but the two paths have materially different financial profiles — differences in capital required, cash flow timing, risk exposure, valuation methodology, and long-term economics. This post compares the two paths across the dimensions that most directly affect the financial decision.
Capital Required at Closing
The two paths require different capital structures at the point of commitment.
Cold startup. The operator finances the full startup cost through a combination of personal equity injection, commercial debt, and equipment leases. Published commercial lending sources commonly cite an equity injection in the range of 15–35% of total project cost as preferred by lenders for healthcare practice startups, with the specific percentage depending on lender, jurisdiction, and operator profile.
Acquisition. The operator typically finances the purchase price through a combination of personal equity, a practice acquisition loan, and often a seller-held note as a portion of the purchase price. Published dental M&A sources commonly describe acquisition down payment requirements in a lower percentage range than cold startups, particularly when SBA 7(a) financing is used in the US or when the seller holds a portion of the purchase price.
For a given amount of personal capital, an acquisition often puts the operator into a revenue-generating practice at a similar or lower upfront cash commitment than a comparable cold startup, with the caveat that acquisition structures include a goodwill premium that a startup does not.
How a Dental Practice Is Valued in an Acquisition
Understanding valuation methodology matters before evaluating acquisition cash requirements, because the purchase price is the result of the valuation approach applied.
EBITDA-based valuation is the primary methodology used in serious dental practice transactions. EBITDA — earnings before interest, taxes, depreciation, and amortization — is typically "normalized" to reflect what the business would earn under new ownership, with adjustments for owner compensation (typically normalized to fair market associate compensation), non-recurring expenses, personal expenses run through the business, and other seller-specific items. A multiple is then applied to normalized EBITDA to derive valuation. Published dental M&A sources describe typical multiple ranges that vary by practice type — solo general practices at the lower end of the range, multi-provider groups higher, and DSO-acquired practices in competitive markets at the top of published ranges.
Percentage-of-collections is a shortcut commonly used in dental M&A reference content. It is a simplification that produces reasonable approximations for solo general practices with typical operating margins, but can deviate meaningfully from EBITDA-based valuation for specialty practices or practices with unusual expense structures. Serious buyers and their lenders generally rely on the EBITDA method regardless of how a practice is listed.
Asset-based valuation applies when a practice lacks significant goodwill — declining revenue, high patient attrition, outdated equipment, or reputation issues. In these cases valuation defaults toward tangible asset value with minimal goodwill premium.
The valuation methodology that applies to a given practice depends on its specialty, financial profile, and market dynamics. A dental-experienced broker or CPA familiar with practice transactions can advise on the appropriate approach for a specific practice.
Cash Flow Timing
This is often the most consequential difference between the two paths.
A cold startup generates little to no revenue for the first several months after opening. Published dental industry sources generally describe new-practice ramp curves that build progressively over 12 to 18 months before reaching a sustainable patient volume. During the early ramp period, fixed costs — rent, staff, debt service, insurance — continue to be paid with limited offsetting revenue. Working capital reserve is what bridges this gap.
An acquisition starts with an existing patient base, existing insurance credentialing, existing staff, and existing systems. Published dental transition sources generally describe well-executed acquisitions as maintaining a substantial portion of historical revenue in the first year post-acquisition, with some revenue attrition common as patients adjust to new ownership. The result is a materially different cash flow position than a startup: positive operating cash flow from early months, assuming the transition is managed well.
Risk Profile
The two paths carry different risks, not simply different magnitudes of the same risk.
Cold startup risks center on the pace of patient acquisition. If a practice takes longer than modelled to reach sustainable volume, working capital may run short. Other startup risks include construction delays, equipment delivery issues, marketing that underperforms expectations, and in the US context, insurance credentialing delays.
Acquisition risks center on whether the practice performs post-sale as it did pre-sale. If the seller's reported financials overstated normalized earnings, if patient attrition after the sale is higher than typical (often a function of how strongly patients were attached to the seller personally), or if key staff leave during transition, revenue can decline materially. Due diligence — reviewing the practice's financial statements, patient retention data, staff contracts, insurance network participation, and the normalized EBITDA calculation — is the standard mitigation.
Long-Term Economics
Both paths can produce strong long-term outcomes. The trade-off is primarily between certainty and customization.
A well-executed cold startup reflects the operator's specific vision — layout, technology, brand, clinical approach, and team. There are no legacy systems or patient expectations to work around. The upside over a five to ten year horizon can be meaningful, but the path to reach steady-state profitability is longer and carries more risk during the ramp.
A well-executed acquisition reaches steady-state profitability from day one and allows the new owner to optimize an already-functioning business. The upside ceiling may be lower in percentage terms than a greenfield startup, but the trajectory is more predictable and the risk profile is structurally different.
Which Path Tends to Fit Which Operator
There is no universal answer to the acquisition-versus-startup question; both paths are legitimate and both have produced successful practices. General observations from published dental industry sources and practice advisors include:
Cold startup tends to suit operators with substantial personal cash reserves or access to family equity, strong marketing and business-building instincts, entry into an underserved market, a strong preference for controlling practice design and brand from the beginning, and the ability to tolerate 12 to 18 months of reduced personal income during the ramp.
Acquisition tends to suit operators who need income from the first year (student loan obligations, family financial responsibilities, or mortgage considerations), who bring strong clinical skills but less appetite for entrepreneurial risk, who are entering mature markets where building a patient base cold is more difficult, or who have identified a specific practice with a retiring owner whose patient base and systems transfer well.
The financial difference between the two paths is primarily about the timing of cash flow, the risk profile, the valuation methodology that applies, and the capital structure that supports each. It is not about whether one path is universally better than the other.
For the startup path, the Clinic Cost Estimator models a startup capital requirement by specialty and market. For the acquisition path, the Practice Valuation Reference produces an implied valuation range from EBITDA, revenue, and quality-factor inputs — a reference point for assessing whether a listed price falls within published ranges. Separate Canadian and US models.
Disclaimer: All figures and ranges referenced are drawn from published industry sources and represent general patterns, not estimates for any specific practice. Valuation is market-specific and situation-specific. KlinDeck is not a financial advisor, accountant, lender, or lawyer. Consult qualified professionals before making significant decisions.